BioCentury
ARTICLE | Company News

Galmed Pharmaceuticals, OWL deal

July 13, 2015 7:00 AM UTC

The companies partnered to develop a non-invasive, blood-based companion diagnostic for Aramchol arachidyl amino cholanoic acid to treat non-alcoholic steatohepatitis (NASH). Galmed is conducting the Phase IIb ARREST trial of the synthetic conjugate of cholic acid and arachidic acid to treat NASH. The partners hope to develop a companion diagnostic that would replace liver biopsies and assist in patient selection for a planned Phase III trial of Aramchol. ...